NIH· @NIH · X·· 3 天前AI 评分28
AI 导读
NIH 研究人员开发出选择性 LATS1/2 抑制剂 NCGC-6782,在临床前模型中加速伤口闭合。该分子由 AT-7867 改造而来,增强对 LATS 的抑制作用并减少对 AKT 等其他靶点的脱靶效应。小鼠皮肤伤口隔日局部给药后,愈合时间比未治疗组提前数天,未观察到毒性迹象。
正文
A new NIH-developed compound could help wounds heal faster. Researchers designed a more selective inhibitor that accelerated wound closure in preclinical models, offering a promising new approach for regenerative medicine and tissue repair. https://x.com/i/article/2121758420965425152
来源:NIH · x.com